Wells Fargo Downgrades Enzymotec (ENZY) to Market Perform
- Wall Street stocks fall as weak GDP growth spreads rate-cut gloom
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil settles higher as weak U.S. economic growth offset by supply concerns
- Dollar sags after US GDP and inflation surprise, except against yen
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
Enzymotec (ENZY) Misses Q3 EPS by 4c; Trims FY16 Outlook; CEO Katz Resigns
November 16, 2016 7:33 AM ESTEnzymotec (NASDAQ: ENZY) reported Q3 EPS of $0.03, $0.04 worse than the analyst estimate of $0.07. Revenue for the quarter came in at $11.4 million versus the consensus estimate of $13.3 million.
CEO Change:
Enzymotec also announced that Dr. Ariel Katz, the Companys President and Chief Executive Officer, will depart the Company by the end of May 2017, and the Board of Directors has initiated a... More